Navigation Links
Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
Date:9/5/2007

/p>

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, preclinical and internal and partnered clinical programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's planned clinical trials may not proceed at the time Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Basel, Switzerland (PRWEB) September 30, 2014 ... advanced software solutions for drug discovery and ... the FUNGITECT consortium has chosen Genedata Selector ... next-generation sequencing (NGS) data. FUNGITECT is a ... of invasive fungal diseases via individualized anti-fungal ...
(Date:9/30/2014)... 2014 iLab Solutions announced the results ... which focuses on core facility operations, growth and ... face today. , In its 4th year running, a ... is the year-over-year decrease in the percentage of revenue ... be feeling the constraints of this trend. When asked, ...
(Date:9/30/2014)... Rainbow Scientific, Inc. (RSI), a North ... an online store to add customer convenience in ... and manufactured by Biological Industries, Inc. , Products ... Nutristem® serum-free, xeno-free reagents for human mesenchymal stem ... culture. , The online store also offers ...
(Date:9/30/2014)... September 30, 2014 The ... IACRN), a non-profit organization based in Pittsburgh, Pennsylvania, ... and Safety (ACRES), a Massachusetts non-profit charitable ... alliance agreement, setting the stage for multiple collaborative ... clinical research quality and safety through specialized nursing ...
Breaking Biology Technology:FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3
... May 27, 2009 Senomyx, Inc. (Nasdaq: ... technologies to discover and develop novel flavor ingredients for ... the appointment of David L. Linemeyer, Ph.D., to the ... 20 years of experience in directing biology research programs ...
... May 27 The atherosclerosis vaccine,development program by ... EUROTRANS-BIO call. The respective project is being carried ... The aim of,atherosclerosis vaccination is to increase the ... the blood and thus reduce the occurrence of,harmful ...
... Oncothyreon Inc. (Nasdaq: ONTY ) (TSX: ONY) announced ... shares of its common stock and warrants to purchase 2,909,244 ... $11.1 million on May 26, 2009. Oncothyreon sold the shares ... one share and a warrant to purchase 0.75 shares of ...
Cached Biology Technology:SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY 2SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY 3AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 2AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 3Oncothyreon announces closing of $11.1 million registered direct financing 2
(Date:9/30/2014)... (PCE) in drinking water may increase the risk ... new study led by a Boston University School ... in the journal Environmental Health , compared ... 1,766 women in Cape Cod, Ma., where water ... early 1980s by the installation of vinyl-lined asbestos ...
(Date:9/30/2014)... in urban and farm runoff in Hawaii is causing ... , The study, published Tuesday in the peer-reviewed ... the runoff ends up in algae that the turtles ... eyes, flippers and internal organs. , Scientists at Duke ... and Atmospheric Administration (NOAA) conducted the study to better ...
(Date:9/30/2014)... Here,s some hope: A new research report published in ... , explains how scientists developed a synthetic version ... embryo development in human and mouse eggs similar to ... cell during fertilization. , "We believe that the results ... our understanding of human fertilization by providing a precise ...
Breaking Biology News(10 mins):Contaminated water linked to pregnancy complications, BU study finds 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Synthetic sperm protein raises the chance for successful in vitro fertilization 2
... Tobacco smoking by pregnant women has long been ... adverse effects on the development of a fetus. ... outcomes, including low birth weight, sudden infant death syndrome, ... and nicotine use in offspring. Despite this extensive literature, ...
... to help fertilize crops, it is vital to understand the ... Burkholderia , for example, includes dangerous disease-causing pathogens one ... but also many species that are safe and important ... good and evil be told apart? Yes, UCLA life scientists ...
... - Scientists at A*STAR,s Institute of Molecular and Cell ... sequenced and analysed the genome of the elephant shark. ... human and other vertebrate genomes revealed why the skeleton ... The findings carry potential implications for human bone disease ...
Cached Biology News:Maternal stress hormones and maternal smoking increase daughter's risk of nicotine dependence 2UCLA life scientists, colleagues differentiate microbial good and evil 2UCLA life scientists, colleagues differentiate microbial good and evil 3Elephant shark genome provides new insights into bone formation and adaptive immunity in humans 2Elephant shark genome provides new insights into bone formation and adaptive immunity in humans 3
...
Chicken polyclonal to UCK2 ( Abpromise for all tested applications). Antigen: Full length protein, corresponding to amino acids 1-261 of Human UCK2 Entrez Gene ID: 7371 Swiss Protein ID: ...
... (rEK) is a highly purified preparation of ... serine protease which recognizes the identical cleavage ... has similar enzymatic activity. Novagen&'s enzyme is ... purified to yield the highest activity available, ...
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
Biology Products: